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The effect of chamomile intake on lipid  
profile in patients with diabetes and  
related metabolic disorders. A systematic 
review and meta-analysis of randomized 
controlled trials
AbSTRACT
background. The current study sought to provide 
a robust examination of the evidence for the efficacy 
of chamomile on lipid profile in diabetics. 
Methods. PubMed, Scopus, web of Science, and 
Cochrane Library were systematically searched to find 
randomized controlled trials (RCTs) assessing the im-
pact of chamomile intake on lipid profile, up to 17 Au-
gust 2020. To obtain weighted mean difference (wMD) 
and 95% confidence intervals (CIs), a random-effects 
model was applied. A random-effects meta-regression 
was ran to detect the potential source of inter-study 
heterogeneity. Publication bias was checked using 
begg’s and Egger’s tests. 
Results. Four trials, comprising 254 participants, were 
included to the meta-analysis. In comparison with con-
trols, total cholesterol (TC) (wMD = –22.40, 95% CI = 
= [–37.85, –6.96], P = 0.004, I2 = 59.1%) was signifi-
cantly decreased in the groups receiving chamomile. 
In contrast, serum triglycerides (Tg) (wMD = –17.47, 
95% CI = [–44.44, 9.50], P = 0.20, I2 = 74.3%), high 
density lipoproteins cholesterol (HDl-C) (wMD = 0.63, 
95% CI = [–1.38, 2.64], P = 0.53, I2 = 0.0%), and low 
density lipoprotein cholesterol (lDl-C) (wMD = –10.94, 
95% CI = [–23.71, 1.81], P = 0.09, I2 = 71.3%) were 
not significantly altered by chamomile consumption. 
Conclusion. The present meta-analysis demonstrates 
that chamomile can elicit significant reductions in 
serum TC, but not Tg, HDl-C and lDl-C in diabetics. 
Moreover, further large-scale and well-designed RCTs 
are required to confirm the veracity of these findings. 
(Clin Diabetol 2021; 10; 4: 375–381)
Key words: chamomile, lipid profile, diabetes, 
review, meta-analysis
Background
Diabetes mellitus (DM) is a group of metabolic 
disorders characterized by high blood glucose level over 
a prolonged period [1, 2] and causes due to insufficient 
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insulin secretion or insulin resistance or both [3]. Nowa-
days, DM has become a global health problem all over 
the world, the number of diabetic patients was about 171 
million in 2000 and is predicted to reach 366 million by 
2030 [4]. Chronic diabetes leads to the several complica-
tions such as diabetic ketoacidosis (DKA), hyperosmolar 
coma, chronic kidney diseases (CKD), neuropathy and 
cardiovascular disorders, but the most common of them 
is hyperlipidemia [5–8]. It is suggested that poor glycemic 
control disrupts the function of fat metabolism enzymes 
[9] and stress oxidation increases the lipid oxidation that 
cause macrovascular and microvascular diseases [10]. 
Hence, health care systems is trying to find an urgent 
strategy to prevent diabetes all over the world. One of 
these strategies is to use medicines such as atorvastatin 
[11], that might have some ramifications including muscle 
cramps, diarrhea and memory loss [12]. Therefore, in cases 
who have statin intolerance, it is suggested to use tradi-
tional medicine to control diabetes risk factors [13, 14]. 
Chamomile, also termed “betmatricaria chamomil-
laor matricariarecutita”, is one of the most popular herbal 
drinks in the world [15]. It is known for its wide range of 
therapeutics effects, such as anti-inflammatory, antioxi-
dant, anticancer, antimicrobial, antidiabetics and sedative 
features [16]. The main components of chamomile are 
flavonoids, sesquiterpenes, coumarins and polyacety-
lenes, in addition to containing numerous other chemical 
constituents with pharmacological properties [17]. Those 
compounds recuperate the sensitivity of insulin, which in 
turn improves lipid profile through the following mecha-
nisms. Lipoprotein lipase is an insulin sensitive enzyme, 
which is primarily responsible for triglyceride (TG) hydroly-
sis, so by improving insulin sensitivity, the function of this 
enzyme improves, and serum TG levels decrease. Another 
involved mechanism can be contributed to peroxisome 
proliferator-activated receptors (PPARs). PPARs, by acting 
as lipid sensors, are major metabolic regulators in the 
body and control every aspect of fatty acid metabolism. 
The expression of this gene decreases serum TG, increases 
high- density- lipoprotein-cholesterol (HDL-C) [18, 19]. 
Therefore, in the present study we sought to illuminate 
the effect of chamomile on the lipid profile in diabetics by 
conducting the first systematic review and meta-analysis 
of randomized controlled trials.
Methods
The study is conducted based on the guidance 
of Cochrane Handbook [20] and the review protocol 
registered with PROSPERO (CRD42020213991). 
Search strategy
Two researchers independently undertook the pro-
cess of the systematic search in the online databases, 
PubMed, Scopus, Web of Science, and Cochrane Library, 
to detect relevant articles, published up to 17 August 
2020, that assessed the efficacy of chamomile intake 
on lipid profile in adults. The search strategy was re-
fined by consulting with an epidemiology expert and 
designed as a combination of the search terms shown 
in supplementary material. To augment the sensitivity 
of our search strategy, the wild-card term “*” was 
included and the reference lists of relevant articles or 
reviews and Google Scholar were hand-scanned. Any 
doubts were resolved through a discussion with the 
corresponding author.
Inclusion and exclusion criteria 
Two independent reviewers assessed the detected 
studies against the following inclusion criteria: 1) rand-
omized controlled trials (RCTs) with parallel design; and 
2) studies that assessed the effects of chamomile on 
lipid profile (TC or/and TG or/and HDL-C or/and LDL-C) 
in diabetic patients. Studies were excluded if they were 
animal-designed, reviews, conference abstracts, edito-
rials, observational-designed, book chapters, or brief 
reports and not randomized. In addition, papers that 
lacked any essential data, for example, non-extractable 
or unconvertable data, studies without a suitable con-
trol group, and trials with combined supplementation 
of clinical effective nutrients or/and medicines besides 
chamomile, which were not comparable between 
intervention and control group, were removed. If any 
disagreements arose, consensus was achieved through 
discussion with the corresponding author.
Data extraction
After selecting the eligible studies for the meta-
analysis, two authors extracted the following data: first 
authors’ last name, publication date, country, study 
design, participants’ characteristics, a dosage of cham-
omile, control type, intervention duration, quality of 
trials, mean changes and standard deviations (SDs) for 
each outcomes in pre-treatment and post-treatment. In 
instances standard error (SE) or 95% confidence inter-
vals (CIs) were reported instead of SD, the appropriate 
formulas were used to convert them to SD. If needed, 
e-mails were sent to the corresponding author of the 
related articles. The Cochrane Risk of Bias Tool [21] was 
used, by two independent reviewers, to qualify the 
included RCTs, and explore the potential risk of bias in 
the following domains: random sequence generation, 
allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete 
outcome data, selective outcome reporting and other 
biases. “Low”, “high” or “unclear” terms were used to 
score each item. RevMan V5.3 was executed to draw 
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any relevant graph. Corresponding author resolved any 
discrepancy between authors.
Statistical analysis
Mean changes of the interested outcomes and the 
relevant SD were obtained by executing the following 
formulas, respectively: [mean-post – mean-baseline], 
SD = √([SD2-baseline + SD2-post] – [2r × SD-baseline 
× SD-post]), assuming correlation coefficient (r) as 0.5 
[22], SD = SE/√n.
The meta-analysis was conducted using STATA 
software v13 (Stata Corp.). A random-effects model 
was applied to pool weighted mean differences (WMD) 
and corresponding 95% confidence intervals (CIs) 
[22]. The statistical heterogeneity among the studies 
was assessed using Cochrane Q test (I2 statistic (high 
≥ 50%, low < 50%) and p-value) [22]. In presence of 
high statistical heterogeneity among studies, random-
effects meta-regression was done to investigate the 
potential sources. Sensitivity analysis was conducted to 
assess the impact of each study on the pooled results 
by removing one study, consecutively [22]. Potential 
publication bias was evaluated by applying Begg’s and 




Figure 1 presents the search process; briefly, 418 
references were identified through our systematic 
search, of which 127 were omitted as duplicates. The 
remaining papers were screened by title and abstract, 
resulting in the exclusion of another 280. Finally, 11 
full-text articles were assessed for eligibility, and four 
RCTs were selected for meta-analysis [24–27].
Table 1 outlines demographic characteristics of the 
included studies, which were conducted in Iran and 
published between 2015– 2018. A total of 252 par-
ticipants, aged between 24.38 and 55.33 years, were 
pooled in the meta-analysis. Moreover, the duration of 
the chamomile intervention was 4 [25], 8 [27], and 12 
[24, 26] weeks, respectively. All of the included trials 
were graded as ‘Good’ in quality (Table 2).
Findings from meta-analysis
The results of the meta-analysis are shown in Table 3. 
Pooled effects of the included trials demonstrated that 
chamomile yielded a significant reduction in serum TC 
(WMD = –22.40, 95% CI = [–37.85, –6.96], P = 0.004, 
I2 = 59.1%), in comparison with controls. In contrast, 
the meta-analysis indicated that chamomile intake 
did not cause a statistically significant change in the 
concentration of serum TG (WMD = –17.47, 95% CI 
= [–44.44, 9.50], P = 0.20, I2 = 74.3%), HDL-C (WMD 
= 0.63, 95% CI = [–1.38, 2.64], p = 0.53, I2 = 0.0%), 
and LDL-C (WMD = –10.94, 95% CI = [–23.71, 1.81], 
P = 0.09, I2 = 71.3%).
Publication bias and sensitivity analysis
As shown in Table 3, none of the outcomes dem-
onstrated a publication bias based on both Begg’s and 
Egger’s test. In addition, sensitivity analysis indicated 
that pooled results were not affected by removing any 
individual trial.
Figure 1. Flow diagram of the study selection process
Records identied thouhg PubMed (n = 19), 
Scopus (n = 202), Web of Science (n = 197) 
searching (n = 418)
Duplicates removed 
(n = 127)
Records screended by title and abstract
(n = 291)
Full-text articles assessed for eligibility
(n = 11)
Studies included in quantitative synthesis 
(meta-analysis) (n = 4)




















Full-text articles excluded, with 
reasons (n =7)
• Animal-design study (n = 3)
• Duplicate data (n = 2)
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Meta-regression
The meta-regression analysis was conducted based 
on the age of participants, dose of chamomile, and 
intervention duration, to discern the possible sources 
of statistical heterogeneity across studies; however, we 
were unable to detect the potential sources (Table 3).
Discussion
To the best of our knowledge, the present study 
is the first comprehensive meta-analysis evaluating 
the effects of chamomile on lipid profile. In line with 
evidence from Aljubouri et al. [28] and Al-Bayati [29], 
the present meta-analysis showed that TC was signifi-
cantly ameliorated following chamomile consumption, 
but did not yield a statistically meaningful change in 
the concentration of serum TG, HDL-C, and LDL-C. The 
impact of chamomile extract on the serum lipid profile 
in diabetic animals has been already investigated [30, 
31]. For instance, Najla et al. [32] indicated that altera-
tions in the serum levels of HDL-C, TG, TC, and LDL-C 
were substantially different from those in the control 
groups, following chamomile extract administration in 
diabetic rats. In addition, chamomile tea consumption 
in patients with T2DM yielded a substantial reduction 
in serum TG, TC, and LDL-C levels after 8 weeks of 
treatment [27], and similar impacts in obese mice were 
reported [33]. It has been suggested that the antihy-
perlipidemic activity of chamomile may be due to its 
potential properties including the high concentration 
essential oil [34], the presence of chlorogenic acid in 
the chamomile flowers [35, 36], modulation of peroxi-
some proliferator-activated receptor (PPARs) [37], as 
well as its antioxidant action [38, 39]. Regarding PCOS, 
chamomile improves lipid oxidation via decreasing 
LDL-C and TG, and increasing serum HDL-C through its 
phytoestrogen compounds [24].
PPARa ligands [40] and PPARa activation have been 
demonstrated to up-regulate genes expression that 
participate in lipoprotein and lipid metabolism, in ad-
dition to oxidation of fatty acids in the skeletal muscle 
[41]. Indeed, in Weidner et al. [33], this putative role 
was explored, and the results indicated that ethanolic 
Matricaria chamomilla L. flowers extract mediated gene 
expression of PPARa target genes. 
Table 1. Study characteristics of the included RCTs
First author Publication  
year













Rafraf et al. 2015 Iran T2D 64 50.19 9 Water 8 ØTC, ØTG, 
ØLDL-C
Heidary et al. 2018 Iran PCOS 80 24.38 1.11 Capsule 12 *
Kaseb et al. 2018 Iran T2D 44 55.33 20 Water 4 ØTC, ØLDL-C
Kermanian et al. 2018 Iran Depressed 
T2D
64 51.95 7.5 Water 12 *
Ø A significant reduction; * No significant change observed; TC: total cholesterol; TG: triglycerides; LDL-C: low density lipoprotein-cholesterol; T2D: type 2 
diabetes; PCOS: poly cystic ovary         
Table 2. The results of the quality assessment using Cochrane Collaboration Tool













Rafraf et al. + + + ? + + Good
Heidary et al. + + + ? + + Good
Kaseb et al. + + + ? + + Good
Kermanian et al. + + + ? + + Good
 + low risk; –  high risk; ?  unclear
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In addition, the chamomile plant sterols have been 
shown to promote the catabolism of lipids in mice cells. 
Ultimately, it appears that chamomile can reduce and 
regulate the absorption of cholesterol, whilst its’ hydroal-
coholic chamomile extract contains ascorbic acid which 
also reduces the cholesterol content [42]. It has been 
shown that phytoestrogens can control the homeostasis 
of cholesterol by increasing the secretion of fecal bile 
acid, changing the synthesis of bile acids, and raising the 
liver cholesterol secretion [43]. Furthermore, phytosterols 
lead to reduced LDL cholesterol and TG levels through 
interfering with the cholesterol absorption [24].
Several evidences also showed that chamomile 
ameliorated oxidative stress and improved antioxidant 
defense system because of its antioxidants agents such 
as apigenin, luteolin and quercetin. It also has been 
shown that chamomile had a potential role in aug-
menting the antioxidant enzymes, including superoxide 
dismutase (SOD) and catalase (CAT), that catalyzes the 
dismutation of the superoxide radical into ordinary 
molecular like oxygen and hydrogen peroxide [44]. 
Since antioxidants play an important role in protecting 
unsaturated fatty acids against reactive oxygen species, 
they improve lipid profile by reducing lipid peroxidation 
[45]. In this view, it seems that chamomile might have 
a potential role in improving lipid profile abnormality.
While reports of allergies from chamomile, such 
as bronchial constriction and skin rashes, have been 
reported; most people can use this herb without any 
complication, and reports tend to be scarce. It is nec-
essary to mention that chamomile tea should not be 
consumed by pregnant individuals, as it can stimulate 
uterine contractions; whilst it also has a blood-diluting 
effect, and thus, people who use anticoagulant drugs 
should not use it [46]. Studies on the use of chamomile 
to improve lipid profile in humans are limited, and 
despite the tentative positive findings in the present 
study related to TC further human studies are needed 
for better discern of the biologic effects of chamomile. 
Strengths and limitations
To our knowledge, this study is the first meta-
analysis to have comprehensively evaluated the effects 
of chamomile on lipid profile. However, like any other 
study, the current meta-analysis has some limitations 
that should be noted. First, a limited number of pub-
lished RCTs in the field could affect the between-study 
heterogeneity [47]. Second, although we conducted 
a meta-regression, we could not detect the potential 
source of heterogeneity. Third, although we did not 
restrict our search strategy to regions, only articles 
emanating from Iran were found, and thus, the find-
ings cannot be generalized to other nations. Fourth, 
the participants were not restricted to any specific 
disease, so, further consideration of disease-specific 
processes and contraindications must be taken. Finally, 
in some cases, when we requested more details about 
patients’ characteristics and relevant information from 
corresponding authors, we did not receive an appropri-
ate response.
Conclusion
The present meta-analysis demonstrates that 
chamomile can elicit significant reductions in serum 
TC, but not TG, HDL-C and LDL-C. Further long term 
RCTs are needed in the field, with a particular focus on 
other cultures, doses, and diseases.
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